The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Market Size Of The Hepatitis Therapeutics Market Expected To Change Between 2026 And 2030?
The size of the hepatitis therapeutics market has shown consistent growth in recent years. It is projected to expand from $19.08 billion in 2025 to $19.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.7%. Historically, this growth was influenced by factors such as the high prevalence of hepatitis B and C infections, the introduction of interferon-based therapies, the expansion of public vaccination initiatives, increased blood screening and diagnostic awareness, and government-led viral hepatitis control programs.
The hepatitis therapeutics market is projected to experience consistent expansion over the upcoming years, reaching a valuation of $23.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. This anticipated growth is linked to factors such as the increasing adoption of direct-acting antivirals, a surge in investments towards innovative immune modulators, enhanced treatment accessibility in developing regions, higher diagnosis rates facilitated by screening initiatives, and the ongoing development of pipeline therapies targeting all genotypes. Key trends during this period are expected to encompass the growing use of direct-acting antivirals for hepatitis C, an intensified emphasis on combination treatments for chronic hepatitis, the expansion of vaccination efforts to prevent hepatitis, a move towards long-term management relying on oral antivirals, and increased utilization of online and specialty pharmacies for accessing medications.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9956&type=smp
Which Major Factors Are Driving The Expansion Of The Hepatitis Therapeutics Market?
An increasing volume of clinical trials is projected to fuel the expansion of the hepatitis therapeutic market in the future. These trials represent research investigations focused on assessing novel treatments, drugs, or interventions involving human subjects. They are vital for advancing new hepatitis treatments, as they establish a strict and ethical structure for evaluating the safety and effectiveness of prospective therapies, thereby guaranteeing patients receive the most impactful and advantageous treatments accessible. For example, data from December 2024, reported by the Association of the British Pharmaceutical Industry, a UK-based nonprofit organization, indicated that industry-initiated clinical trials within the UK rose from 411 trials in 2022 to 426 trials in 2023, representing a 3.7% increase. Consequently, the rising count of clinical trials is a key impetus for the expansion of the hepatitis therapeutics market.
How Is The Hepatitis Therapeutics Market Structured Across Different Segments?
The hepatitis therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Drug Class: Oral Antivirals, Immune Modulators
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers
Subsegments:
1) By Hepatitis A: Vaccines, Post-Exposure Prophylaxis (PEP)
2) By Hepatitis B: Antiviral Medications, Immune Modulators, Vaccines
3) By Hepatitis C: Direct-Acting Antivirals (DAAs), Ribavirin, Interferon-Based Therapies
4) By Other Disease Types: Hepatitis D, Hepatitis E
Which Trends Are Shaping The Future Of The Hepatitis Therapeutics Market?
Major companies operating in the hepatitis therapeutics market are increasingly focusing on strategic agreements to develop new therapies, aiming to gain a competitive edge. These strategic agreements are formal contracts between two or more parties that delineate the terms of their cooperation to achieve shared business objectives. For instance, in October 2023, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology firm, announced an agreement to obtain an exclusive license for JNJ-3989. This particular compound is an investigational subcutaneous RNA interference (RNAi) therapeutic designed for the treatment of chronic hepatitis B (CHB). JNJ-3989 is a novel RNAi therapeutic specifically targeting the hepatitis B virus (HBV) X protein, which is essential for HBV replication and viral persistence.
Which Major Players Dominate The Hepatitis Therapeutics Market?
Major companies operating in the hepatitis therapeutics market are Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Biocon Biopharmaceuticals Pvt. Ltd.
Read the full hepatitis therapeutics market report here:
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
Which Region Currently Holds The Largest Share Of The Hepatitis Therapeutics Market?
North America was the largest region in the hepatitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Hepatitis Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9956&type=smp
Browse Through More Reports Similar to the Global Hepatitis Therapeutics Market 2026, By The Business Research Company
Hepatitis Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
Hepatitis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report
Liver Diseases Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model